LENZ Therapeutics (NASDAQ:LENZ) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS

LENZ Therapeutics (NASDAQ:LENZ) announced its earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04), Zacks reports.

LENZ Therapeutics Price Performance

Shares of LENZ opened at $25.52 on Thursday. LENZ Therapeutics has a 1 year low of $14.42 and a 1 year high of $38.93. The stock has a 50 day simple moving average of $24.09 and a 200-day simple moving average of $27.02.

Analyst Upgrades and Downgrades

Separately, TD Cowen started coverage on LENZ Therapeutics in a research note on Tuesday. They set a “buy” rating and a $60.00 target price for the company. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, LENZ Therapeutics currently has an average rating of “Buy” and an average price target of $39.50.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.